8 completed. 8 Phase 2, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 8 | Completed 8 |
| Phase 1 | 2 | Completed 2 |
Follow MenACWY: new trials by email Literature Review of MenACWY trials Research Report on MenACWY
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study to Expand Safety and Immunogenicity Data With Shigella Bioconjugate Vaccine (Shigella4V2) in 9-month-old Infants. Shigella4V2, MenACWY - Shigellosis | Phase 2 | Completed | LimmaTech Biologics AG | 110 | 2025-04-07 | 2026-08-07 |
| A Study on the Safety, Reactogenicity, and Immune Response to the GVGH iNTS-GMMA Vaccine Against Invasive Nontyphoidal Salmonella in Adults, Children, and Infants iNTS-GMMA Dose C, iNTS-GMMA Dose B, iNTS-GMMA Dose A - Salmonella Infections | Phase 2 | Completed | GlaxoSmithKline | 180 | 2024-01-15 | 2026-09-21 |
| A Study of a Candidate COVID-19 Vaccine (COV001) ChAdOx1 nCoV-19, MenACWY, ChAdOx1 nCoV-19 full boost - Coronavirus | Phase 1 / Phase 2 | Completed | University of Oxford | 1077 | 2020-04-23 | 2025-09-03 |
| A Study to Determine If a New Shigella Vaccine is Safe, Induces Immunity and The Best Dose Among Kenyan Infants Shigella 4V, MenACWY, Rabies - Shigellosis | Phase 1 / Phase 2 | Completed | LimmaTech Biologics AG | 597 | 2019-09-02 | 2026-06-23 |
| A Study of 2-dose Vaccination Regimen of Ad26.ZEBOV and MVA-BN-Filo in Infants Ad26.ZEBOV, MVA-BN-Filo, MenACWY - Ebola Virus Disease | Phase 2 | Completed | Janssen Vaccines & Prevention B.V. | 108 | 2019-08-19 | 2025-05-25 |
| A Study to Investigate the Safety and Immunogenicity of Different Formulations of GSK Biologicals' Meningococcal ACWY Conjugate Vaccine (GSK3536820A and Menveo) Administered to Healthy Adolescents and Young Adults 10 to 40 Years of Age MenACWY liquid, MenACWY - Meningitis, Meningococcal | Phase 2 | Completed | GlaxoSmithKline | 1707 | 2018-08-30 | 2021-02-17 |
| Study to Assess Potential Immune Interference When GlaxoSmithKline (GSK) Biologicals' MenABCWY Vaccine is Administered to Healthy Subjects Aged 10-25 Years MenABCWY vaccine, rMenB+OMV NZ (Bexsero) vaccine, MenACWY (Menveo) vaccine - Meningitis, Meningococcal | Phase 2 | Completed | GlaxoSmithKline | 520 | 2018-07-09 | 2020-02-12 |
| Effectiveness, Immunogenicity and Safety of Meningococcal ABCWY Vaccine Administered to Healthy Adolescents MenABCWY, Placebo, MenACWY - Meningococcal Disease | Phase 2 | Completed | Novartis Vaccines | 305 | 2014-05-01 | 2018-09-12 |
Dysentery, Bacillary (2) · Meningitis (2) · Meningitis, Meningococcal (2) · Meningococcal Infections (2) · COVID-19 (1) · Coronavirus Infections (1) · Hemorrhagic Fever, Ebola (1) · Salmonella Infections (1)
GlaxoSmithKline (3) · LimmaTech Biologics AG (2) · Janssen Vaccines & Prevention B.V. (1) · Novartis Vaccines (1) · University of Oxford (1)
Kenya (2) · Brazil (1) · Czechia (1) · Estonia (1) · Finland (1) · France (1) · Ghana (1) · Guinea (1) · Mexico (1) · Russia (1) · Sierra Leone (1) · South Africa (1) · Spain (1) · Turkey (Türkiye) (1) · United Kingdom (1)
Andrew Pollard, Prof (1) · Josphat Kosgei, MD (1) · Mainga Hamaluba, MD (1) · Richard Omore, PhD (1)
PMID 30061029, PMID 32702298, PMID 33306989, PMID 33335322, PMID 33617777, PMID 34480858, PMID 34787449, PMID 35257644, PMID 36369456, PMID 37138460, PMID 37858585
2017 (2)